Shortcuts 2022 2021 2020

2022

  • Fierce Biotech
    BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study Read More

2021

  • Empowered Patient Podcast
    Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman Read More

  • UW Health
    UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease Read More

  • Greenbay CBS
    Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’ Read More

  • WBay.com
    Neenah man gets new lease on life after trial heart procedure Read More

  • Henry Ford Health System
    Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms Read More

  • Cell & Gene
    Inside BioCardia's CardiAMP Cell Therapy Read More

2020

  • BioTuesdays
    BioCardia developing autologous and allogenic cardiovascular cell therapies Read More

  • Pharmaceutical Technology
    BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure Read More

News

06 Dec

Fierce Biotech

BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
Read More
01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More

press releases

22 Dec
2022 BioCardia Letter to Shareholders
15 Dec
2022 BioCardia Announces $3.6 Million Private Placement of Common Stock
06 Dec
2022 BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
09 Nov
2022 BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
02 Nov
2022 BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
03 Oct
2022 BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS